Literature DB >> 22221894

Mutant Hras(G12V) and Kras(G12D) have overlapping, but non-identical effects on hepatocyte growth and transformation frequency in transgenic mice.

Marxa L Figueiredo1, Timothy J Stein, Adam Jochem, Eric P Sandgren.   

Abstract

BACKGROUND: Mouse hepatocarcinogenesis is associated with mutations in Hras, but infrequently in Kras. The effect on carcinogenesis of developmental age at the time of ras mutation remains unknown. AIM: We sought to compare quantitatively the effects of expressing mutant H- or Kras genes in fetal vs. adult mouse liver.
METHODS: We established an inducible system of gene expression in mouse liver to define disease pathogenesis associated with activation of oncogene expression.
RESULTS: Diffuse expression of either oncogene in fetal or adult hepatocytes caused hepatomegaly. For mutant Hras(G12V), this phenotype was almost fully reversible and accompanied by apoptosis, indicating that maintenance of hepatomegaly requires continuous Hras(G12V) expression. We also examined the effect of ras expression on growth of transplanted hepatocytes in an in vivo system that allows us to quantify hepatocyte growth effects in both permissive and restrictive hepatic growth environments. Mutant Kras(G12D) had no effect on hepatocyte growth in this system. In contrast, Hras(G12V) induced increased hepatocyte focus growth in quiescent liver, the hallmark of a cell autonomous growth stimulus. Hras(G12V) also increased the fraction of donor hepatocyte foci that displayed extreme growth, a characteristic of preneoplastic lesions.
CONCLUSIONS: The primary effect of diffuse, whole-liver expression of either mutant ras gene in fetal or adult mouse liver is diffuse and progressive hepatic growth. Hras(G12V) mutation influences hepatocarcinogenesis by conferring cell autonomous growth potential upon foci of expressing cells and by increasing the risk of neoplastic progression. Kras(G12D) does not share these latter carcinogenic effects in mouse liver.
© 2012 John Wiley & Sons A/S.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22221894      PMCID: PMC4319543          DOI: 10.1111/j.1478-3231.2011.02732.x

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  31 in total

1.  Tight control of gene expression in mammalian cells by tetracycline-responsive promoters.

Authors:  M Gossen; H Bujard
Journal:  Proc Natl Acad Sci U S A       Date:  1992-06-15       Impact factor: 11.205

2.  Quantification of mRNA using real-time RT-PCR.

Authors:  Tania Nolan; Rebecca E Hands; Stephen A Bustin
Journal:  Nat Protoc       Date:  2006       Impact factor: 13.491

3.  Activation of the Ha-, Ki-, and N-ras genes in chemically induced liver tumors from CD-1 mice.

Authors:  S Manam; R D Storer; S Prahalada; K R Leander; A R Kraynak; B J Ledwith; M J van Zwieten; M O Bradley; W W Nichols
Journal:  Cancer Res       Date:  1992-06-15       Impact factor: 12.701

4.  Gender-dependent hepatic alterations in H-ras12V transgenic mice.

Authors:  Ai-Guo Wang; Hyung-Bae Moon; Mi-Ran Lee; Chae Young Hwang; Ki-Sun Kwon; Seong-Lan Yu; Yong-Sung Kim; Mirang Kim; Jin-Man Kim; Sang-Keun Kim; Tae-Hoon Lee; Eun-Yi Moon; Dong-Seok Lee; Dae-Yeul Yu
Journal:  J Hepatol       Date:  2005-06-02       Impact factor: 25.083

5.  Quantifying growth and transformation frequency of oncogene-expressing mouse hepatocytes in vivo.

Authors:  Marxa L Figueiredo; Kristin M Wentworth; Eric P Sandgren
Journal:  Hepatology       Date:  2010-08       Impact factor: 17.425

Review 6.  Mutations in ras genes in experimental tumours of rodents.

Authors:  R C Sills; G A Boorman; J E Neal; H L Hong; T R Devereux
Journal:  IARC Sci Publ       Date:  1999

7.  Activated oncogenes in B6C3F1 mouse liver tumors: implications for risk assessment.

Authors:  S H Reynolds; S J Stowers; R M Patterson; R R Maronpot; S A Aaronson; M W Anderson
Journal:  Science       Date:  1987-09-11       Impact factor: 47.728

8.  Temporal control of gene expression in transgenic mice by a tetracycline-responsive promoter.

Authors:  P A Furth; L St Onge; H Böger; P Gruss; M Gossen; A Kistner; H Bujard; L Hennighausen
Journal:  Proc Natl Acad Sci U S A       Date:  1994-09-27       Impact factor: 11.205

Review 9.  Mutations in the ras proto-oncogene: clues to etiology and molecular pathogenesis of mouse liver tumors.

Authors:  R R Maronpot; T Fox; D E Malarkey; T L Goldsworthy
Journal:  Toxicology       Date:  1995-08-25       Impact factor: 4.221

10.  Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes.

Authors:  Jo Vandesompele; Katleen De Preter; Filip Pattyn; Bruce Poppe; Nadine Van Roy; Anne De Paepe; Frank Speleman
Journal:  Genome Biol       Date:  2002-06-18       Impact factor: 13.583

View more
  1 in total

1.  Comparison of liver oncogenic potential among human RAS isoforms.

Authors:  Sook In Chung; Hyuk Moon; Hye-Lim Ju; Dae Yeong Kim; Kyung Joo Cho; Silvia Ribback; Frank Dombrowski; Diego F Calvisi; Simon Weonsang Ro
Journal:  Oncotarget       Date:  2016-02-09
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.